Real World Evidence on clinical outcomes with Aztreonam-Avibactam (ATM-AVI) Grant
Funding Amount
Up to US $250,000
Deadline
Deadline not published
Grant Type
Foundation
Overview
Real World Evidence on clinical outcomes with Aztreonam-Avibactam (ATM-AVI)
This RFP invites research proposals aimed at assessing clinical outcomes associated with the use of Aztreonam-Avibactam (ATM-AVI) in real world clinical settings.
In scope are adult patients with suspected or documented infections due to aerobic gram negative organisms. Eg. CRE-MBL, Stenotrophomonas maltophilia, treated with ATM-AVI.
Geographic Scope
Countries where ATM-AVI is available (ex-US) and used in clinical practice at the time of RFP release, including but not limited to parts of EU, the United Kingdom, the Middle East, and selected Asia-Pacific markets. Proposals from institutions already participating in Pfizer-sponsored or funded, overlapping ATM-AVI RWE study may be considered out of scope. Proposals involving studies on patients that have received ATM-AVI via pre-approval or pre-launch expanded access routes may be considered out of scope
Project Types and Area of Interest
Potential applicants are requested to submit research proposals to study the below outcomes following treatment with ATM-AVI for adult patients with suspected or documented infections with aerobic gram negative organisms e.g. CRE-MBL, S. maltophilia.
Clinical effectiveness with ATM-AVISafety outcomes with ATM-AVIMicrobiological outcomes with ATM-AVIHealth Economic outcomes with ATM-AVI (in addition to any of the above)
Proposals may include data from special populations such as – immunocompromised (solid organ transplant or haemato-oncological patients)
Funding Range and Project Length
Individual projects requesting up to $50,000 USD will be considered. The total budget for this RFP is $ 250,000 USDMaximum project length is 12 months
What The Pfizer Foundation Inc actually gave
Source: IRS Form 990-PF, 2024
- Grants in 2024
- 9,306
- Total given
- $23.24M
Focus Areas & Funding Uses
Fields of Work
- Science research
- Healthcare
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma Grant
The Pfizer Foundation Inc
Amount
US $50,000 - US $200,000
Deadline
Deadline not published
Pfizer Clostridioides difficile (C. difficile) Research Collaboration Grant
The Pfizer Foundation Inc
Amount
Up to US $500,000
Deadline
Deadline not published
Bronchoscopy Research Grant
Intuitive Foundation
Amount
Up to US $75,000
Deadline
January 4, 2027
Listed date — confirm with the funder
Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)
National Institutes of Health
Amount
Up to $250,000
Deadline
January 7, 2027
Genomic Data Generation Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$6,600,000 total
Deadline
January 8, 2027
George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
National Institutes of Health
Amount
$5,300,000 total
Deadline
February 1, 2027
Ready to apply for Real World Evidence on clinical outcomes with Aztreonam-Avibactam (ATM-AVI) Grant?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Real World Evidence on clinical outcomes with Aztreonam-Avibactam (ATM-AVI) Grant. Now let's win it.